Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...
SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback